Nasal COVID-19 vaccine spray could join the market as ENA respiratory begins its phase 1 study the vaccine candidate

AUSTRALIA – ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, has initiated a Phase I human safety study of INNA-051. The fast-acting and convenient nasal spray has been developed to activate innate immunity in the nose, the primary entry portal of most respiratory viral infections. Ena Respiratory adds that the vaccine could be used prior to or shortly after exposure to a virus, prompting the body to respond faster to protect patients from illness and reduce the chance…

Read More